Equities

Mochida Pharmaceutical Co Ltd

Mochida Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)3,360.00
  • Today's Change25.00 / 0.75%
  • Shares traded23.90k
  • 1 Year change+7.69%
  • Beta0.5179
Data delayed at least 20 minutes, as of Jun 02 2023 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Mochida Pharmaceutical Co Ltd is a Japan-based company principally engaged in the production and sale of drugs. The Pharmaceutical-related segment is engaged in the manufacture, purchase and sale of pharmaceutical products. The Company also conducts brokerage and management of real estate properties, the maintenance and management of buildings, the agency of personal affairs, accounting and purchasing businesses. The Healthcare segment is involved in the manufacture, purchase and sale of quasi drugs and cosmetic products.

  • Revenue in JPY (TTM)103.26bn
  • Net income in JPY6.65bn
  • Incorporated1945
  • Employees1.54k
  • Location
    Mochida Pharmaceutical Co Ltd1-1, Ichigayahommura-choSHINJUKU-KU 162-0845JapanJPN
  • Phone+81 333587211
  • Fax+81 333587887
  • Websitehttps://www.mochida.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Eiken Chemical Co Ltd43.27bn5.74bn65.44bn745.009.771.128.321.51153.90153.901,160.641,337.740.6722.743.75--8.918.8311.0511.3447.3946.3913.2612.162.48--0.0831.280.63964.34-7.7517.070.621615.33
Towa Pharmaceutical Co Ltd208.86bn2.20bn90.87bn4.08k40.010.63434.210.435144.0944.094,219.212,781.160.59381.643.97--0.62584.730.86346.3934.8141.271.058.061.15--0.541319.7426.1117.46-86.17-19.4614.6613.63
Shin Nippon Biomedical Laboratories Ltd25.09bn6.06bn99.04bn994.0016.343.7812.943.95145.57145.57602.69629.610.51972.066.12--12.539.4719.5614.3452.0050.0024.1224.390.7886--0.415819.1141.378.61-14.98--37.23--
Torii Pharmaceutical Co Ltd49.75bn2.77bn99.50bn563.0034.990.829330.772.0098.7398.731,770.514,166.290.38432.642.3088,360,570.002.146.352.347.2447.4750.375.5716.186.68--0.0020.834.06-5.2816.89-3.52-18.6615.81
Kyorin Pharmaceutical Co Ltd113.27bn4.72bn114.55bn2.22k21.510.809813.381.0182.4282.421,976.682,189.400.6511.402.65--2.723.203.363.9344.2948.724.175.102.03--0.14567.807.330.47120.12-6.4019.42-2.16
Zeria Pharmaceutical Co Ltd68.38bn6.20bn126.85bn1.74k17.041.6110.271.85140.14140.141,548.071,484.790.52741.534.14--4.793.377.415.4072.3771.459.086.520.75156.270.429441.0314.871.1556.418.305.403.30
Mochida Pharmaceutical Co Ltd103.26bn6.65bn129.36bn1.54k18.900.968313.881.25177.78177.782,778.763,470.180.64142.033.47--4.134.865.025.9453.3752.206.447.363.41----41.67-6.28-0.6644-37.09-5.9214.62-1.21
ispace Inc989.24m-11.40bn132.38bn220.00------133.82-211.47-211.4718.35-43.55----------------55.88---1,152.22--1.36-97.841.53--46.74---180.75------
Sawai Group Holdings Co Ltd200.34bn12.67bn144.73bn2.97k11.450.71784.740.7224288.73288.734,567.634,604.670.56151.473.03--3.601.144.951.5631.2636.926.412.241.2287.950.255880.413.373.58144.81-2.0110.060.00
Kissei Pharmaceutical Co Ltd67.49bn10.53bn148.49bn1.83k12.550.681610.072.20228.30228.301,463.584,204.650.29391.682.96--4.633.215.023.4747.9752.3915.7611.105.20--0.007636.533.23-1.83-18.523.083.7410.76
KAKEN PHARMACEUTICAL CO., LTD.72.98bn5.44bn164.69bn1.16k24.830.985920.572.26144.37144.371,942.573,636.170.44032.193.69--3.288.173.759.5654.2055.557.4516.094.53--0.027444.00-4.01-5.81-43.03-22.173.160.00
JCR Pharmaceuticals Co Ltd34.34bn3.77bn182.99bn816.0046.783.3831.645.3330.1630.16275.36418.050.35760.53612.57--3.949.636.6614.6774.1374.3411.0319.320.819--0.303126.30-32.7710.77-74.004.2053.6725.21
Data as of Jun 02 2023. Currency figures normalised to Mochida Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

9.38%Per cent of shares held by top holders
HolderShares% Held
Nomura Asset Management Co., Ltd.as of 28 Apr 2023715.20k1.86%
The Vanguard Group, Inc.as of 05 May 2023659.42k1.71%
Asset Management One Co., Ltd.as of 30 Sep 2022587.00k1.53%
BlackRock Fund Advisorsas of 04 May 2023345.10k0.90%
Daiwa Asset Management Co. Ltd.as of 28 Apr 2023329.90k0.86%
Nikko Asset Management Co., Ltd.as of 02 May 2023320.10k0.83%
Norges Bank Investment Managementas of 31 Dec 2022238.86k0.62%
Dimensional Fund Advisors LPas of 04 May 2023167.00k0.43%
Mitsubishi UFJ Kokusai Asset Management Co., Ltd.as of 31 Oct 2022147.10k0.38%
Charles Schwab Investment Management, Inc.as of 04 May 2023101.72k0.26%
More ▼
Data from 31 Dec 2022 - 31 Mar 2023Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.